Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Breast Cancer
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Breast Cancer
    MRI Detects Contralateral Breast Tumours Missed by Conventional Screening Methods - (DGNews)
    TopAbstracts in Breast Cancer 03/09/2010 - (DGNews)
    Early-Stage Disease Explains Worse Survival in Male Breast Cancer: Presented at SSO - (DGDispatch)
    Lymphoedema Index Useful for Lymphoedema Evaluation Following Breast Cancer Surgery: Presented at SSO - (DGDispatch)
    Surgeon Volume Has No Effect on Lymphoedema Occurrence in Older Patients With Breast Cancer: Presented at SSO - (DGDispatch)

    News archive

     Recent webcasts/CME - Breast Cancer
    • Current Research on New Treatments for Patients With Difficult-to-Treat Advanced Breast Cancer: An Interactive Discussion of Challenges, Opportunities, and Practical Considerations
    • Overcoming Challenges in Difficult-to-Treat Advanced Breast Cancer: What Are the Latest Advances?
    • Overcoming Challenges in Difficult-to-Treat Advanced Breast Cancer: How to Apply the Evidence to Clinical Practice?
    • Patient Scenarios for Everyday Practice: Managing Advanced HER2-Positive Breast Cancer Throughout the Disease Continuum
    • Surgical Margins in Breast Conservation Therapy: How Much Should We Excise?

      Webcasts/CME archive

       Recent cases - Breast Cancer
        Solitary Adrenal Metastasis From Invasive Ductal Breast Cancer: An Uncommon Finding
        Metastatic Breast Cancer Deluding As A Papular Skin Rash
        Breast Pseudotumoral Radionecrosis as a Late Radiation-Induced Injury: A Case Report
        Large Family with Both Parents Affected by Distinct BRCA1 Mutations: Implications for Genetic Testing
        Bilateral Swollen Eyelids Occurring During Adjuvant Treatment with Tamoxifen for Early Breast Cancer

        Cases archive
          




        my personal edition > breast cancer > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Trial Confirms Efficacy of Weekly Paclitaxel for Metastatic Breast Cancer: Presented at ASCO

        By M. M. Pennell

        NEW ORLEANS, LA -- June 10, 2004 -- Results of a randomized trial that compared weekly paclitaxel to an every-3-week regimen for treatment of metastatic breast cancer "confirm what oncologists have known and are doing in practice -- weekly paclitaxel is superior," said lead investigator Andrew Seidman, MD, Memorial Sloan Kettering Cancer Center in New York, New York.

        The trial results also confirmed that adding trastuzumab to chemotherapy is not effective in women with breast cancer that is not overexpressing the HER-2 gene. Dr. Seidman presented the late-breaking results of the Cancer and Leukemia Group B (CALCB) 9840 trial on June 5th at the American Society of Clinical Oncology 40th Annual Meeting.

        The analysis was based on 580 women recruited for the study and 120 women enrolled in CALGB 9342, a somewhat controversial approach but one that was approved by the National Cancer Institute, Dr. Seidman said. The 9342 patients were taking paclitaxel at the standard dose. He said this unique protocol allowed the investigators to answer the dosing frequency question more quickly, while "conserving patient resources."

        Dr. Seidman and colleagues stratified the study subjects according to line of therapy (first or second) and HER-2 status, and randomly assigned them to 1 of 4 treatment arms -- standard paclitaxel (every 3 weeks), weekly paclitaxel, standard paclitaxel administered with trastuzumab, or weekly paclitaxel with trastuzumab.

        Response rates were 40% in the weekly paclitaxel arm and 28% in the standard regimen arm (P =.017). Weekly paclitaxel was also associated with a significantly longer time to progression, a secondary end point of the study (P =.0008; adjusted hazard ratio, 1.45). Again, the addition of trastuzumab to paclitaxel did not have a significant effect in women with HER-2-negative metastatic breast cancer.

        Weekly paclitaxel was associated with less myelosuppression but more neurotoxicity than the standard regimen, Dr. Seidman said in an interview.

        "When considered together with the results of CALGB 9342, where an increase in paclitaxel dose did not improve outcome, the present results are consistent with the concept that the frequency of drug administration -- or density -- may account for the improved efficacy that was observed," Dr. Seidman said during his presentation.


        [Presentation title: CALGB 9840: Phase III Study of Weekly Paclitaxel Via 1-Hour Infusion Versus Standard 3h Every Third Week in the Treatment of Metastatic Breast Cancer With Trastuzumab for HER2 Positive and Randomized for T in HER2 Normal MBC. Abstract 512]



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2010 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send